SynthesisFrontiers in immunology2026
Immune-inflammatory biomarkers and immune features in metabolic dysfunction-associated steatotic liver disease: a bibliometric study.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous liver disease involving metabolic dysfunction, inflammatory activity, immune activation, and fibrotic remodeling. Immune-inflammatory biomarkers and immune-related features may support disease characterization, fibrosis assessment, and risk stratification, but the knowledge structure of this subfield remains unclear. This study used bibliometric methods to map the development, contributors, intellectual structure, and emerging trends of immune-inflammatory biomarker and immune-feature research in MASLD/NAFLD. Methods: Publications were retrieved from the Web of Science Core Collection (WoSCC), with Scopus used for cross-database validation. After manual screening and data refinement, 268 WoSCC publications from 2000 to 2025 were retained for primary analysis. CiteSpace and VOSviewer were used to analyze publication trends, contributing countries, institutions, journals, authors, collaboration networks, keyword co-occurrence, keyword bursts, and reference co-citation clusters. Results: Annual publication output increased markedly after 2022. China contributed the largest number of publications, whereas the United States showed the strongest collaborative link strength. Aarhus University was the leading institution, while Henning Grønbæk and Konstantin Kazankov were the leading authors by publication output. Co-citation and keyword analyses indicated that the field is organized around overlapping domains, including systemic inflammatory indices, hepatic inflammation and histologic injury, immune-cell and macrophage-centered features, fibrosis assessment, treatment-response readouts, and prognostic stratification. Recent keyword bursts highlighted oxidative stress, macrophages, pathogenesis, and liver fibrosis. Scopus validation showed broadly consistent temporal and thematic patterns. Discussion: Overall, this subfield is rapidly expanding toward fibrosis-oriented stratification, immune-cell phenotyping, and clinically scalable inflammatory biomarker research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.